Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.

Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, Vincent T, Demarest J, Adkison K, Quercia R.

AIDS Res Hum Retroviruses. 2020 Jan;36(1):13-18. doi: 10.1089/AID.2019.0171. Epub 2019 Oct 21.

2.

Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.

Vannappagari V, Ragone L, Henegar C, van Wyk J, Brown D, Demarest J, Quercia R, St Clair M, Underwood M, Gatell JM, de Ruiter A, Aboud M.

Antivir Ther. 2019;24(6):393-404. doi: 10.3851/IMP3331.

PMID:
31503008
3.

First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

Heera J, Valluri SR, Craig C, Fang A, Thomas N, Meyer RD, Lewis ME, van der Ryst E, Demarest J.

New Microbiol. 2019 Apr;42(2):101-107. Epub 2019 Apr 29.

4.

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.

Demarest J, Underwood M, St Clair M, Dorey D, Brown D, Zolopa A.

AIDS Res Hum Retroviruses. 2018 Apr;34(4):343-346. doi: 10.1089/AID.2017.0184. Epub 2018 Mar 22.

5.

Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.

van der Ryst E, Heera J, Demarest J, Knirsch C.

Ann N Y Acad Sci. 2015 Jun;1346(1):7-17. doi: 10.1111/nyas.12777. Epub 2015 May 11.

PMID:
25962411
6.

Reliable genotypic tropism tests for the major HIV-1 subtypes.

Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JF, Drummond F, Harrigan PR, Churchill MJ, Gorry PR.

Sci Rep. 2015 Feb 25;5:8543. doi: 10.1038/srep08543.

7.

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.

Heera J, Valluri S, Craig C, Fang A, Thomas N, Meyer RD, Demarest J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19519. doi: 10.7448/IAS.17.4.19519. eCollection 2014.

8.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

9.

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR.

Clin Infect Dis. 2013 Jun;56(11):1659-66. doi: 10.1093/cid/cit105. Epub 2013 Feb 21.

PMID:
23429552
10.

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

Lee GQ, Harrigan PR, Dong W, Poon AF, Heera J, Demarest J, Rinehart A, Chapman D, Valdez H, Portsmouth S.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):979-84. doi: 10.1089/AID.2012.0338. Epub 2013 Mar 6.

11.
12.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J.

Antiviral Res. 2013 Jan;97(1):60-5. doi: 10.1016/j.antiviral.2012.11.002. Epub 2012 Nov 16.

PMID:
23165088
13.

HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC.

J Virol. 2010 Jul;84(13):6505-14. doi: 10.1128/JVI.00374-10. Epub 2010 Apr 21.

14.

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.

AIDS Res Hum Retroviruses. 2010 Jan;26(1):13-24. doi: 10.1089/aid.2009.0132.

15.

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31. doi: 10.1128/AAC.01057-08. Epub 2008 Dec 15.

16.

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. doi: 10.1128/AAC.01055-08. Epub 2008 Dec 15.

17.

In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.

Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC.

J Clin Pharmacol. 2008 Oct;48(10):1179-88. doi: 10.1177/0091270008322178. Epub 2008 Aug 1.

PMID:
18676693
18.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.

PMID:
18614865
19.

Privacy concerns of patients and nurse practitioners in primary care--an APRNet study.

Olsen DP, Dixon JK, Grey M, Deshefy-Longhi T, Demarest JC.

J Am Acad Nurse Pract. 2005 Dec;17(12):527-34.

PMID:
16293161
20.

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.

Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S.

AIDS. 2005 Sep 23;19(14):1443-8.

PMID:
16135896
21.

Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.

Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF.

J Virol. 2003 Jun;77(12):6743-52.

22.

5-HT1A receptor activity disrupts spontaneous alternation behavior in rats.

Seibell PJ, Demarest J, Rhoads DE.

Pharmacol Biochem Behav. 2003 Feb;74(3):559-64.

PMID:
12543219
23.

Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression.

Demarest JF, Jack N, Cleghorn FR, Greenberg ML, Hoffman TL, Ottinger JS, Fantry L, Edwards J, O'Brien TR, Cao K, Mahabir B, Blattner WA, Bartholomew C, Weinhold KJ.

AIDS Res Hum Retroviruses. 2001 Sep 20;17(14):1333-44.

PMID:
11602044
24.

Body image: gender, ethnic, and age differences.

Demarest J, Allen R.

J Soc Psychol. 2000 Aug;140(4):465-72.

PMID:
10981375
25.

Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.

Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, Lazzarin A, Kaufmann D, Casorati G, Corey L, Pantaleo G.

Blood. 2000 Mar 1;95(5):1743-51.

PMID:
10688833
26.

Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection.

Haynes BF, Hale LP, Weinhold KJ, Patel DD, Liao HX, Bressler PB, Jones DM, Demarest JF, Gebhard-Mitchell K, Haase AT, Bartlett JA.

J Clin Invest. 1999 Mar 15;103(6):921. No abstract available.

27.

Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection.

Haynes BF, Hale LP, Weinhold KJ, Patel DD, Liao HX, Bressler PB, Jones DM, Demarest JF, Gebhard-Mitchell K, Haase AT, Bartlett JA.

J Clin Invest. 1999 Feb;103(4):453-60. Erratum in: J Clin Invest 1999 Mar;103(6):921.

28.

Applications of Ion Microscopy and In Situ Electron Microscopy to the Study of Electronic Materials and Devices.

Hull R, Demarest J, Dunn D, Stach EA, Yuan Q.

Microsc Microanal. 1998 May;4(3):308-316.

PMID:
9767668
29.

Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection.

Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S, Daucher MB, Cohen OJ, Denis F, Biddison WE, Sekaly RP, Fauci AS.

Eur J Immunol. 1997 Dec;27(12):3166-73.

PMID:
9464802
30.

Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection.

Pantaleo G, Soudeyns H, Demarest JF, Vaccarezza M, Graziosi C, Paolucci S, Daucher M, Cohen OJ, Denis F, Biddison WE, Sekaly RP, Fauci AS.

Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9848-53.

31.

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.

Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, Perrin L, Tambussi G, Lazzarin A, Sekaly RP, Soudeyns H, Corey L, Fauci AS.

Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8.

32.

Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations.

Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, Demarest J, Pantaleo G, Fauci AS, Moretta L.

Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12433-8.

33.

Perception of body shape by underweight average, and overweight men and women.

Demarest J, Langer E.

Percept Mot Skills. 1996 Oct;83(2):569-70.

PMID:
8902032
34.

Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection.

Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, Saag MS, Shaw GM, Quinn TC, Cohen OJ, Welbon CC, Pantaleo G, Fauci AS.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4386-91.

35.

Effect of pH buffers on proton secretion from gastric oxyntic cells measured with vibrating ion-selective microelectrodes.

Demarest JR, Morgan LM.

Biol Bull. 1995 Oct-Nov;189(2):219-20. No abstract available.

PMID:
8541412
36.

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.

Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, et al.

Nat Med. 1995 Apr;1(4):330-6.

PMID:
7585062
37.

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al.

N Engl J Med. 1995 Jan 26;332(4):209-16.

38.

Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.

Pantaleo G, Demarest JF, Vaccarezza M, Graziosi C, Bansal GP, Koenig S, Fauci AS.

Eur J Immunol. 1995 Jan;25(1):226-31.

PMID:
7843235
39.

Expression of a wide T cell receptor V beta repertoire in human T lymphocytes derived in vitro from embryonic liver cell precursors.

Poggi A, Demarest JF, Costa P, Biassoni R, Pella N, Pantaleo G, Mingari MC, Moretta L.

Eur J Immunol. 1994 Sep;24(9):2258-61.

PMID:
8088340
40.

Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.

Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, Borrow P, Saag MS, Shaw GM, Sekaly RP, et al.

Nature. 1994 Aug 11;370(6489):463-7.

PMID:
8047166
41.

Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection.

Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, Muro-Cacho C, Fauci AS.

Immunol Rev. 1994 Aug;140:105-30. Review.

PMID:
7821924
42.

Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.

Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sékaly RP, Fauci AS.

Science. 1994 Jul 8;265(5169):248-52.

PMID:
8023143
43.

Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins.

Rebai N, Pantaleo G, Demarest JF, Ciurli C, Soudeyns H, Adelsberger JW, Vaccarezza M, Walker RE, Sekaly RP, Fauci AS.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1529-33.

44.

HIV-1 infection in the lymphoid organs.

Graziosi C, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, Butini L, Montroni M, Fauci AS.

AIDS. 1993 Nov;7 Suppl 2:S53-8. Review.

PMID:
8161447
45.

Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.

Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, Fauci AS.

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6405-9.

46.

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS.

Nature. 1993 Mar 25;362(6418):355-8.

PMID:
8455722
47.
48.

Electrophysiology of the parietal cell.

Demarest JR, Loo DD.

Annu Rev Physiol. 1990;52:307-19. Review. No abstract available.

PMID:
2184758
49.

Activation of apical chloride channels in the gastric oxyntic cell.

Demarest JR, Loo DD, Sachs G.

Science. 1989 Jul 28;245(4916):402-4.

PMID:
2474200
50.

Effects of salinity, hypophysectomy, and prolactin on whole-animal transepithelial potential in the tilapia Oreochromis mossambicus.

Young PS, McCormick SD, Demarest JR, Lin RJ, Nishioka RS, Bern HA.

Gen Comp Endocrinol. 1988 Sep;71(3):389-97.

PMID:
2847953

Supplemental Content

Loading ...
Support Center